Key Highlights
• Veru reported a fiscal Q3 2026 net loss of $7 million, or $0.30 per diluted share, beating the $0.32 per share loss estimate by 6.25 percent.
• The company completed full enrollment of its Phase IIb PLATEAU clinical trial evaluating enobosarm plus semaglutide in 239 older patients, with interim 32-week data expected in the first calendar quarter of 2027.
• Veru received a USPTO Notice of Allowance for a key method-of-use Patent covering enobosarm in combination with weight loss drugs, with expected patent protection until at least October 2044.
• Cash, cash equivalents, and restricted cash totaled $23.9 million as of June 30, up from $15.8 million at September 30, 2025, following a $23.3 million public Equity offering.
PLATEAU Trial Enrollment Completed, Setting Up Near-Term Data Milestones
Veru Inc. ( Nasdaq :VERU) reported a fiscal third quarter net loss of $7 million, or $0.30 per diluted share, an improvement from a $7.3 million loss a year earlier, as the company advanced its lead obesity program toward key data readouts. Veru is a late clinical-stage biopharmaceutical company developing enobosarm, an oral selective androgen receptor modulator intended to preserve muscle mass and physical function in patients losing weight on GLP-1 receptor agonist therapy, alongside sabizabulin, an anti-inflammatory candidate for atherosclerotic cardiovascular disease. The company completed full enrollment of its Phase IIb PLATEAU clinical trial with 239 patients, evaluating enobosarm 3 mg alongside semaglutide in adults aged 65 and older with obesity, positioning the company for an interim 32-week data readout expected in the first calendar quarter of 2027 and final 68-week data expected by the fourth calendar quarter of 2027.
The PLATEAU study builds on Veru's earlier Phase IIb QUALITY trial, which the company said was the first human study to demonstrate that older obesity patients on a GLP-1 receptor agonist face elevated risk of accelerated lean mass loss and physical function decline, and that adding enobosarm helped preserve lean mass and reduce the proportion of patients experiencing clinically significant physical function decline. Management said the new trial specifically targets whether enobosarm can help patients break through the weight loss plateau commonly observed after roughly a year of GLP-1 therapy, a phenomenon the company believes may be partly driven by non-selective muscle loss stimulating appetite.
Key Patent Allowance Extends Intellectual Property Protection to 2044
Veru received a Notice of Allowance from the U.S. Patent and Trademark Office for a method-of-use patent covering compositions of enobosarm combined with weight loss drugs for quality weight loss, with claims spanning scenarios including concurrent administration with semaglutide, sequential addition after semaglutide monotherapy, and continued use after semaglutide discontinuation. Once issued, the patent is expected to provide protection until at least October 3, 2044, and management described the allowance as validating the novelty of combining a muscle-preserving therapy with GLP-1 receptor agonists, a combination the company said the patent office found non-obvious.
Management said the company continues to prosecute additional pending patent applications covering combinations of enobosarm with weight loss drugs beyond semaglutide, as well as a novel oral modified-release enobosarm formulation that, if issued, would extend patent protection to at least May 2046. Executives characterized the current allowance as an important first step in building out a broader intellectual property portfolio protecting the company's combination therapy approach across the wider GLP-1 drug class.
Novo Nordisk Supply Agreement Supports Trial Execution and Strategic Positioning
Under a supply agreement entered into with Novo Nordisk (NYSE:NVO) in June, Veru remains solely responsible for conducting and sponsoring the PLATEAU trial, while Novo Nordisk supplies Wegovy to the company at no charge for use in the study, and Veru retains full global development and commercialization rights to enobosarm. As part of the agreement, Veru granted Novo Nordisk a right of first negotiation should the company seek to develop, commercialize, or license enobosarm in combination with any Novo Nordisk GLP-1 product in the future, while providing Novo Nordisk with study updates and insights into obesity and weight management trial design and conduct.
Management noted that Medicare began covering select GLP-1 weight loss drugs, including Wegovy and Zepbound, effective July 1, 2026, and pointed to Medicare Part D data showing 41.5 percent of the 47.4 million enrolled beneficiaries, or approximately 20 million people, have obesity, a population the company believes represents a substantial addressable market for enobosarm as a complementary therapy should it advance toward approval.
Conclusion
Veru's fiscal third quarter reflects meaningful clinical and intellectual property progress on its lead enobosarm program, with full enrollment now completed in the pivotal PLATEAU trial and a key patent allowance extending protection for the company's combination therapy approach to 2044. The company's near-term financial position has been strengthened by a recent equity raise, though Veru remains unprofitable and dependent on the clinical and regulatory success of enobosarm to eventually reach commercialization. The interim 32-week PLATEAU data expected in the first calendar quarter of 2027, along with continued prosecution of the company's broader patent portfolio, are likely to be the key catalysts shaping investor perception of the program over the coming year.






Please wait processing your request...